Summary
Abstract: In 2012, Promega introduced NanoLuc, an ATP-independent marine luciferase mutant exhibiting a high photon production rate in the presence of a synthetic luciferin analog, furimazine. However, NanoLuc has several unfavorable features, including low tissue penetration of its blue emission, and limited substrate solubility and stability. Recent studies (including our efforts) have partially addressed these issues, but there are remaining key hurdles that prevent a broader adoption of NanoLuc-derived bioluminescence systems for in vivo animal imaging. The overall objective of this 4-year
